संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

greenstone llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: essential hypertension: control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc)

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions  for patients with: congestive heart failure: cirrhosis of the liver accompanied by edema and/or ascites: the nephrotic syndrome: essential hypertension: control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progra

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan institutional inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: congestive heart failure: - for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; - the treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; - the treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: - aldosterone levels may be exceptionally high in this cond

इसराइल - अंग्रेज़ी - Ministry of Health

teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - spironolactone 25 mg - comprimé - 25 mg - spironolactone 25 mg - spironolactone

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - spironolactone 100 mg - comprimé - 100 mg - spironolactone 100 mg - spironolactone

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - spironolactone 100 mg - comprimé pelliculé - 100 mg - spironolactone 100 mg - spironolactone

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - spironolactone 25 mg - comprimé pelliculé - 25 mg - spironolactone 25 mg - spironolactone

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - spironolactone 50 mg - comprimé pelliculé - 50 mg - spironolactone 50 mg - spironolactone

स्पेन - स्पेनी - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

orion corporation - espironolactona - comprimido - 25 mg - espironolactona 25 mg + mg + mg - espironolactona